Finding Your Footing in the Shifting Landscape of Multiple Sclerosis
Premiere Date: Wednesday, January 13, 2021This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- ABIM (MOC)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, January 13, 2022
Note: Credit Is No Longer Available
 | Michael K. Racke, MD (Moderator) Neurology Medical Director Quest Diagnostics Secaucus, NJ |
 | Anne H. Cross, MD Professor of Neurology Manny and Rosalyn Rosenthal and Dr. John L. Trotter Multiple Sclerosis Center Chair in Neuroimmunology Washington University School of Medicine St. Louis, MO |
 | Mitzi J. Williams, MD Neurologist and Multiple Sclerosis Specialist Founder and CEO Joi Life Wellness Group Multiple Sclerosis Center Smyrna, GA |
Historically, diagnosing and managing multiple sclerosis (MS) has been difficult. Research uncovering the immune-mediated mechanisms of MS emergence, relapse, and progression has led to development of biomarkers that are now central to diagnosis and treatment decisions, as well as to the development of immune-targeted disease-modifying therapies (DMTs) that can induce long-term remission. Most DMTs are used in continuous or maintenance/escalation therapy regimens, and disease activity typically recurs when these drugs are discontinued. In contrast, pulsed immune reconstitution therapy (IRT) are administered in short courses and provide durable efficacy beyond the active treatment period. This paradigm shift requires health care providers (HCPs) to stay up to date on the range of available and emerging therapies for MS and current guidance on treatment selection and the role of biomarkers in the management of patients with MS.
In this CME Outfitters Live and OnDemand webcast, animated 3-D models will illustrate the immune processes that contribute to MS pathology and serve as targets for immune-directed therapies. Expert faculty will review clinical data supporting the efficacy and safety of novel and emerging immune-directed therapies as well as the role of biomarkers in assessing disease progression and guiding treatment decisions in patients with MS.
At the end of this CE activity, participants should be able to:
- Identify the immunological mechanisms that contribute to MS.
- Assess clinical data supporting the efficacy and safety of novel and emerging immune-directed therapies for MS.
- Integrate biomarkers and imaging techniques to assess disease progression in patients with MS.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Identify the immunological mechanisms that contribute to MS.
- Assess clinical data supporting the efficacy and safety of novel and emerging immune-directed therapies for MS.
- Recognize biomarkers and imaging techniques used to assess disease progression in patients with MS.
Supported by educational grants from Biogen MA, Inc., Bristol-Myers Squibb Company, EMD Serono, Inc., and Sanofi Genzyme.
Neurologists, PAs, nurse practitioners, nurses, and pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Enduring: JA0007185-0000-21-100-H01-P
Type: Knowledge-based
ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learning Formats
Enduring material
ABPN MOC: Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, Finding your Footing in the Shifting Landscape of Multiple Sclerosis has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:
MOC Part II CME Activity
Psychiatry and Neurology
Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to PAs: PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Racke reports he is a consultant for Teva Neuroscience, Inc.
Dr. Cross reports that she receives research support from The Conrad N. Hilton Foundation; and U.S. Department of Defense. She is on the advisory committee for EMD Serono, Inc.; and Genentech, Inc./Roche. She is a consultant for Biogen; Celgene Corporation; EMD Serono, Inc.; Genentech, Inc./Roche; and Novartis.
Dr. Williams reports that she receives research support from EMD Serono, Inc.; Genentech, Inc.; and Novartis. She serves on the advisory committee for AbbVie Inc.; Biogen Idec; Bristol-Myers Squibb Company; EMD Serono, Inc.; Genentech, Inc.; Novartis; and Sanofi Genzyme. She serves as a consultant for AbbVie Inc.; Biogen Idec; Bristol-Myers Squibb Company; EMD Serono, Inc.; Genentech, Inc.; Novartis; and Sanofi Genzyme.
Howard Bliwise, MD (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Rachel Speer, PhD (planning committee) has no disclosures to report.
Evan Luberger (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
TV-123-011321-90
